🎉 Exciting News in Cancer Treatment! 🎉
A revolutionary non-surgical option to treat rectal cancer has just been approved for NHS use! This innovative method, called Papillon, involves using low-dose X-rays to target tumours, offering a promising alternative to surgery. 🌟
The treatment is aimed at fit patients with small tumours (3cm or less) who either opt out of surgery or present high surgical risks. The Papillon technique, which involves an X-ray tube inserted directly to the tumour site, could potentially spare patients from having a stoma, massively boosting their quality of life.
Thanks to pioneering work by Professor Sun Myint from The Clatterbridge Cancer Centre, more patients can now benefit from this cutting-edge treatment. After treating around 3,000 individuals over three decades, he spearheaded the Opera trial, demonstrating that this method can preserve organs in 93% of eligible rectal cancer cases. 🥼🔬
NHS worker Sharon Price shares her story of hope: diagnosed with rectal cancer at 45, the thought of living with a stoma was daunting. Joining the clinical trial gave her a chance to regain her life without it. ❤️
Prof Myint expressed his joy at Papillon being accepted, saying, “It’s wonderful that patients now have a choice of treatment. Many will enjoy a much better quality of life.” Dr Caroline Brammer added that this development will not only benefit patients but also alleviate strain on NHS resources.
With over 41,000 new colorectal cancer cases annually in the UK, this approved treatment offers fresh hope and improved futures for many. 🌈
Let’s celebrate this milestone in cancer care! 🙌
#CancerCare #MedicalInnovation #NHS #PapillonTreatment #QualityOfLife #HealthcareAdvances